SWTX's desmoid tumor drug, Ogsiveo, is driving its top line. The recent FDA nod for Gomekli to treat a rare tumor diversifies its commercial portfolio.

SpringWorks Therapeutics is working on new potential indications for its IP portfolio while running additional trials. See ...

Over the last 7 days, the United States market has dropped by 4.4%, yet it has risen by 7.5% over the past year, with earnings forecasted to grow by 14% annually. In this environment, identifying high ...

Ogsiveo's net product revenues were $172 million in 2024. Last month, the FDA approved SpringWorks’ MEK inhibitor, Gomekli (mirdametinib) for the treatment of adult and pediatric patients 2 ...

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Candel Therapeutics (CADL – Research ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Meiragtx Holdings (MGTX – Research Report) today and set a price ...

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Get Free Report) saw some unusual options trading on Thursday. Traders acquired 13,068 call options on the stock. This is an increase of 223% compared to ...

Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

The U.S. Department of Agriculture announced Wednesday that its Local Food for Schools (LFS) program is ending. The ...